About: Iberdomide, a cereblon modulator promoting degradation of the transcription factors Ikaros and Aiolos, which affect leukocyte development and autoimmunity, is being evaluated for the treatment of systemic lupus erythematosus (SLE).       Sponge   NotDistinct   Permalink

An Entity of Type : owl:Thing, within Data Space : kaiko.getalp.org associated with source document(s)

AttributesValues
rdf:value
  • Iberdomide, a cereblon modulator promoting degradation of the transcription factors Ikaros and Aiolos, which affect leukocyte development and autoimmunity, is being evaluated for the treatment of systemic lupus erythematosus (SLE). (en)
Bibliographic Citation
  • 2022 March 17, Joan T. Merrill, Victoria P. Werth, Richard Furie et al., “Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus”, in The New England Journal of Medicine, volume 386, number 11, →DOI, page 1034: (en)
is skos:example of
Faceted Search & Find service v1.16.118 as of Jul 22 2024


Alternative Linked Data Documents: iSPARQL | ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jul 22 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (125 GB total memory, 52 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software